

Nemours greatly appreciates Senator Rubio's leadership in working with Senate colleagues to ensure inclusion of the RACE for Children Act in the FDA Reauthorization Act of 2017, legislation that passed the Senate today and is expected to be signed by President Trump.

Advancements in pediatric research are a critical priority for Nemours and the children and families we serve. The RACE for Children Act would prompt pharmaceutical companies to examine the safety and efficacy of adult cancer drugs in the pediatric population, based on the relevance of the molecular targets to the growth or progression of a pediatric cancer. We live in a time of great promise and possibility in the research field, and enactment of the RACE for Children Act will help expand the number of cancer therapies studied in the pediatric population, providing the opportunity for the development of more cures.

---

<https://nemours.mediaroom.com/2017-08-04-Statement-by-Vicky-Funanage-PhD-Operational-Vice-President-Research-at-Nemours>